Italian-based biopharmaceutical company Newron Pharmaceuticals has begun the Sarizotan Treatment of Apneas in Rett Syndrome (STARS) study of sarizotan to treat Rett syndrome.

Sarizotan is a new chemical entity and a highly selective compound for specific serotonin or dopamine receptors that modulate the activity of these neurotransmitters in the brain.

Related Company Profiles

View all

STARS is a randomised, double-blind, placebo-controlled trial designed to assess the efficacy, safety and tolerability of sarizotan in treating Rett syndrome.

The trial will run for a duration of six months and is planning to enrol 129 patients who will be divided into three groups of 43 people.

"The initiation of the STARS study is an exciting milestone in our development programme for sarizotan, for the treatment of cardinal abnormal respiratory symptoms of Rett syndrome."

Newron chief medical officer Ravi Anand said: "The initiation of the STARS study is an exciting milestone in our development programme for sarizotan, for the treatment of cardinal abnormal respiratory symptoms of Rett syndrome  including episodes of apnea, hyperventilation and breathing dysrhythmia.

“Newron looks forward to a further collaboration with leading Rett syndrome researchers, experts and advocacy groups to carry out the study and help address patients’ alarming and debilitating symptoms that may contribute to morbidity and mortality in the long term.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Rett syndrome is a severe neurodevelopmental disorder mainly affecting females, causing loss of acquired fine and gross motor skills and the development of neurological, cognitive and autonomic dysfunction.

Most of the patients suffering from Rett syndrome experience apnea, hyperventilation and disordered breathing.

The trial is primarily focused to minimise instances of clinically significant apneas during waking time.

Patients older than 13 years will be administered with 10mg and 20mg doses of sarizotan, or placebo on a daily basis.

Newron is expecting to release top-line results of the study next year.